Book contents
- Frontmatter
- Contents
- Foreword by Anthony S. Tavill
- Preface
- 1 History of iron overload disorders
- 2 Normal iron absorption and metabolism
- 3 Iron toxicity
- 4 Tests for hemochromatosis and iron overload
- 5 Complications of hemochromatosis and iron overload
- 6 Insulin resistance and iron overload
- 7 Infections and immunity
- 8 Classical and atypical HFE hemochromatosis
- 9 Heterozygosity for HFE C282Y
- 10 Porphyria cutanea tarda
- 11 Mitochondrial mutations as modifiers of hemochromatosis
- 12 Hemochromatosis associated with ferroportin gene (SLC40A1) mutations
- 13 Hemochromatosis associated with hemojuvelin gene (HJV) mutations
- 14 Hemochromatosis associated with hepcidin gene (HAMP) mutations
- 15 Hemochromatosis associated with transferrin receptor-2 gene (TFR2) mutations
- 16 Iron overload associated with IRE mutation of ferritin heavy-chain gene (FTH1)
- 17 Hereditary hyperferritinemia-cataract syndrome: IRE mutations of ferritin light-chain gene (FTL)
- 18 Iron overload in Native Africans and African-Americans
- 19 Hereditary atransferrinemia
- 20 Divalent metal transporter-1 (SLC11A2) iron overload
- 21 Iron overload associated with thalassemia syndromes
- 22 Iron overload associated with hemoglobinopathies
- 23 Iron overload associated with pyruvate kinase deficiency
- 24 Iron overload associated with congenital dyserythropoietic anemias
- 25 Hereditary sideroblastic anemias
- 26 Pearson marrow–pancreas syndrome
- 27 Acquired sideroblastic anemias
- 28 Hereditary aceruloplasminemia
- 29 Friedreich ataxia and cardiomyopathy
- 30 Pantothenate kinase (PANK2)-associated neurodegeneration
- 31 Neuroferritinopathies
- 32 GRACILE syndrome
- 33 Neonatal hemochromatosis
- 34 Iron overload due to excessive supplementation
- 35 Localized iron overload
- 36 Management of iron overload
- 37 Population screening for hemochromatosis
- 38 Ethical, legal, and social implications
- 39 Directions for future research
- Index
- Plate section
- References
27 - Acquired sideroblastic anemias
Published online by Cambridge University Press: 01 June 2011
Book contents
- Frontmatter
- Contents
- Foreword by Anthony S. Tavill
- Preface
- 1 History of iron overload disorders
- 2 Normal iron absorption and metabolism
- 3 Iron toxicity
- 4 Tests for hemochromatosis and iron overload
- 5 Complications of hemochromatosis and iron overload
- 6 Insulin resistance and iron overload
- 7 Infections and immunity
- 8 Classical and atypical HFE hemochromatosis
- 9 Heterozygosity for HFE C282Y
- 10 Porphyria cutanea tarda
- 11 Mitochondrial mutations as modifiers of hemochromatosis
- 12 Hemochromatosis associated with ferroportin gene (SLC40A1) mutations
- 13 Hemochromatosis associated with hemojuvelin gene (HJV) mutations
- 14 Hemochromatosis associated with hepcidin gene (HAMP) mutations
- 15 Hemochromatosis associated with transferrin receptor-2 gene (TFR2) mutations
- 16 Iron overload associated with IRE mutation of ferritin heavy-chain gene (FTH1)
- 17 Hereditary hyperferritinemia-cataract syndrome: IRE mutations of ferritin light-chain gene (FTL)
- 18 Iron overload in Native Africans and African-Americans
- 19 Hereditary atransferrinemia
- 20 Divalent metal transporter-1 (SLC11A2) iron overload
- 21 Iron overload associated with thalassemia syndromes
- 22 Iron overload associated with hemoglobinopathies
- 23 Iron overload associated with pyruvate kinase deficiency
- 24 Iron overload associated with congenital dyserythropoietic anemias
- 25 Hereditary sideroblastic anemias
- 26 Pearson marrow–pancreas syndrome
- 27 Acquired sideroblastic anemias
- 28 Hereditary aceruloplasminemia
- 29 Friedreich ataxia and cardiomyopathy
- 30 Pantothenate kinase (PANK2)-associated neurodegeneration
- 31 Neuroferritinopathies
- 32 GRACILE syndrome
- 33 Neonatal hemochromatosis
- 34 Iron overload due to excessive supplementation
- 35 Localized iron overload
- 36 Management of iron overload
- 37 Population screening for hemochromatosis
- 38 Ethical, legal, and social implications
- 39 Directions for future research
- Index
- Plate section
- References
Summary
Acquired sideroblastic anemia is a heterogeneous group of disorders characterized by excessive accumulation of amorphous iron deposits in the mitochondria of erythrocyte precursors. Ring sideroblasts, the sine qua non of sideroblastic anemia, are erythroblasts in Prussian blue-stained marrow aspirates that have numerous iron-positive mitochondria that occur in a perinuclear distribution. In sideroblastic anemia, typical ring sideroblasts have a full or partial ring and usually comprise more than 5% of all erythroblasts (Chapter 25, Fig. 25.1a, b). Other erythroblasts in the same specimens may have markedly increased numbers of iron-positive mitochondria that do not form a perinuclear halo. Acquired sideroblastic anemias encompass two main categories: clonal hematopoietic stem cell disorders classified as myelodysplastic syndromes (MDS); and reversible types of sideroblastic anemia due to drugs, chemicals, or other factors. Heritable types of sideroblastic anemia are described in Chapter 25.
Acquired sideroblastic anemia due to myelodysplastic syndromes
Classification
Refractory anemia with ring sideroblasts (RARS) is characterized by erythroid dysplasia, mitochondrial accumulation of mitochondrial iron-containing ferritin (mitoferrin), defective erythroid maturation, and anemia; some patients also have elevated platelet counts. Other patients with MDS and ring sideroblasts are classified as having refractory cytopenias with multilineage dysplasia and ring sideroblasts (RCMD-RS). MDS in patients with either RARS or RCMD-RS may progress to excess marrow blasts (refractory anemia with excess blasts, RAEB) or acute leukemia.
Pathophysiology
Non-germline mutations in marrow stem cells underlie the pathogenesis of MDS, including MDS subcategories typically associated with ring sideroblasts.
- Type
- Chapter
- Information
- Handbook of Iron Overload Disorders , pp. 277 - 283Publisher: Cambridge University PressPrint publication year: 2010
References
, , Idiopathic acquired refractory sideroblastic anemia: banded chromosome analysis in six patients. Acta Haematol 1977; 57: 15–23.CrossRefGoogle ScholarPubMed
, , , , , . Natural history of idiopathic refractory sideroblastic anemia. Blood 1988; 71: 305–12.Google ScholarPubMed
, . The role of JAK2 Mutations in RARS and other MDS. Hematology Am Soc Hematol Educ Program 2008; 2008: 52–9.Google Scholar
, . JAK2 V617F and ringed sideroblasts: not necessarily RARS-T. Blood 2008; 111: 1748.CrossRefGoogle ScholarPubMed
, , , et al. JAK2 V617F mutation status identifies subtypes of refractory anemia with ringed sideroblasts associated with marked thrombocytosis. Haematologica 2008; 93: 34–40.CrossRefGoogle ScholarPubMed
, , , , , . Apoptosis in refractory anaemia with ringed sideroblasts is initiated at the stem cell level and associated with increased activation of caspases. Br J Haematol 2001; 112: 714–26.CrossRefGoogle ScholarPubMed
, , , et al. Purification and characterization of sideroblasts from patients with acquired and hereditary sideroblastic anaemia. Br J Haematol 2008; 143: 4460.CrossRefGoogle ScholarPubMed
. Iron overload in sideroblastic and other non-thalassemic anemias. In: , , eds. Hemochromatosis: Genetics, Pathophysiology, Diagnosis and Treatment. Cambridge, Cambridge University Press. 2000; 4422.CrossRefGoogle Scholar
, , , , . Abnormalities of flavin monooxygenase as an etiology for sideroblastic anemia. Am J Hematol 2000; 65: 1493.3.0.CO;2-B>CrossRefGoogle ScholarPubMed
, , , et al. Heteroplasmic point mutations of mitochondrial DNA affecting subunit I of cytochrome c oxidase in two patients with acquired idiopathic sideroblastic anemia. Blood 1997; 90: 49612.Google ScholarPubMed
, , , et al. Growth differentiation factor 15 production is necessary for normal erythroid differentiation and is increased in refractory anaemia with ring sideroblasts. Br J Haematol 2009; 144: 251–62.CrossRefGoogle ScholarPubMed
, , , et al. Regulation of growth differentiation factor 15 expression by intracellular iron. Blood 2009; 113: 1555–63.CrossRefGoogle ScholarPubMed
, , , et al. High levels of GDF15 in thalassemia suppress expression of the iron regulatory protein hepcidin. Nat Med 2007; 13: 1096–101.CrossRefGoogle ScholarPubMed
, , , , . Urinary hepcidin excretion in patients with low grade myelodysplastic syndrome. Br J Haematol 2009; 144: 451–2.CrossRefGoogle ScholarPubMed
, , , et al. Iron overload in patients with sideroblastic anaemia is not related to the presence of the haemochromatosis Cys282Tyr and His63Asp mutations. Br J Haematol 1999; 104: 97–9.CrossRefGoogle Scholar
. Strategies for biology- and molecular-based treatment of myelodysplastic syndromes. Curr Drug Targets 2005; 6: 713–25.CrossRefGoogle ScholarPubMed
, , , et al. Antiapoptotic role of growth factors in the myelodysplastic syndromes: concordance between in vitro and in vivo observations. Clin Cancer Res 2005; 11: 6291–9.CrossRefGoogle ScholarPubMed
, , . Hypochromic red blood cells in low-risk myelodysplastic syndromes: effects of treatment with hemopoietic growth factors. Haematologica 2004; 89: 14463.Google ScholarPubMed
. Sideroblastic anemia: death from iron overload. Hosp Pract (Off Ed) 1991; 26 Suppl 3: 55–6.CrossRefGoogle ScholarPubMed
. Consensus statement on iron overload in myelodysplastic syndromes. Am J Hematol 2008; 83: 858–61.CrossRefGoogle ScholarPubMed
. The deleterious effects of iron overload in patients with myelodysplastic syndromes. Blood Rev 2008; 22 Suppl 2: S29–34.CrossRefGoogle ScholarPubMed
, , , et al. Red blood cell transfusion dependence and outcome after allogeneic peripheral blood stem cell transplantation in patients with de novo myelodysplastic syndrome (MDS). Biol Blood Marrow Transpl 2008; 14: 1217–25.CrossRefGoogle Scholar
, , , , , . Deferasirox induces regression of iron overload in patients with myelodysplastic syndromes. Eur J Clin Invest 2009; 39: 406–11.CrossRefGoogle ScholarPubMed
, , , , , . Deferasirox treatment improved the hemoglobin level and decreased transfusion requirements in four patients with the myelodysplastic syndrome and primary myelofibrosis. Acta Haematol 2008; 120: 70–4.CrossRefGoogle ScholarPubMed
, , , et al. Deferasirox in MDS patients with transfusion-caused iron overload—a phase-II study. Ann Hematol 2009; 88: 301–10.CrossRefGoogle ScholarPubMed
. Light and shadows in the iron chelation treatment of haematological diseases. Br J Haematol 2007; 138: 407–21.CrossRefGoogle ScholarPubMed
. Myelodysplasia paranoia: Iron as the new radon. Leuk Res 2009; 33: 1158–63.CrossRefGoogle ScholarPubMed
Iron: The fifth horseman of the apocalypse? Am J Hematol 2009; 84: 263–4.CrossRefGoogle ScholarPubMed
, , , . Antituberculous drugs and sideroblastic anaemia. Br J Haematol 1965; II: 92.CrossRefGoogle Scholar
, , . Anti-tuberculous drugs and sideroblastic anaemia. Br J Clin Pract 1990; 44: 706.Google ScholarPubMed
, , , , . Lead-induced anemia: dose-response relationships and evidence for a threshold. Am J Public Health 1990; 80: 165–8.CrossRefGoogle ScholarPubMed
, . Studies on the pathogenesis of alcohol-induced sideroblastic bone marrow abnormalities. N Engl J Med 1970; 283: 441–6.CrossRefGoogle ScholarPubMed
, , . Clinical studies in alcoholic sideroblastosis. Arch Intern Med 1976; 136: 283–9.CrossRefGoogle ScholarPubMed
, , , . Reversible sideroblastic anemia caused by chloramphenicol. Acta Haematol 1967; 38: 1–10.CrossRefGoogle ScholarPubMed
. Mitochondrial lesions in reversible erythropoietic depression due to chloramphenicol. J Clin Invest 1972; 51: 2085–92.CrossRefGoogle ScholarPubMed
[Blood damage due to chloramphenicol and thiamphenicol.]Schweiz Med Wochenschr 1975; 105: 1078–80.Google Scholar
, . Copper depletion and deficiency in the malnourished infant. Johns Hopkins Med J 1969; 124: 1390.Google ScholarPubMed
, , , . A patient with copper deficiency anemia while on prolonged intravenous feeding. Clin Pediatr (Phila) 1981; 20: 226–8.CrossRefGoogle ScholarPubMed
, . Rapid development of severe copper deficiency in a patient with Crohn's disease receiving parenteral nutrition. J Parenter Enteral Nutr 1999; 23: 1692.CrossRefGoogle Scholar
, , , et al. Anemia and neutropenia in a case of copper deficiency: role of copper in normal hematopoiesis. Acta Haematol 1992; 87: 195.CrossRefGoogle Scholar
, , , , , . Acquired sideroblastic anaemia during treatment of Wilson's disease with triethylene tetramine dihydrochloride. Br J Haematol 1993; 83: 166–8.CrossRefGoogle ScholarPubMed
, , , , . Acquired sideroblastic anaemia induced by a copper-chelating agent. Int J Hematol 1996; 64: 692.CrossRefGoogle ScholarPubMed
, , , . Acquired sideroblastic anaemia after aplastic anaemia caused by D-penicillamine therapy for rheumatoid arthritis. Ann Rheum Dis 1987; 46: 156–8.CrossRefGoogle ScholarPubMed
, , , Excessive zinc ingestion. A reversible cause of sideroblastic anemia and bone marrow depression. JAMA 1990; 264: 1441–3.CrossRefGoogle ScholarPubMed
, , , . Zinc abuse and sideroblastic anemia. Am J Hematol 1993; 42: 227–8.CrossRefGoogle ScholarPubMed
, , . Zinc-induced sideroblastic anemia: report of a case, review of the literature, and description of the hematologic syndrome. Am J Hematol 1994; 46: 1470.CrossRefGoogle ScholarPubMed
, . Case report of sideroblastic anemia caused by ingestion of coins. Am J Hematol 2001; 66: 126–9.3.0.CO;2-J>CrossRefGoogle ScholarPubMed
, , , , , . Acquired sideroblastic anaemia following progesterone therapy. Br J Haematol 1994; 87: 859–62.CrossRefGoogle ScholarPubMed
, , . Effect of pyridoxal 5′-phosphate on oligodeoxynucleotide binding of mouse uterine cytosol estradiol-receptor complexes. Endocrinology 1981; 109: 1196–202.CrossRefGoogle ScholarPubMed
, , . Recurrent thrombocytopenia, erythroid hypoplasia and sideroblastic anaemia associated with hypothermia. Br J Haematol 1982; 51: 451–6.CrossRefGoogle ScholarPubMed